Dropping Ocrelizumab Could Be Good For Biogen Idec's Cash Flow
This article was originally published in The Pink Sheet Daily
Executive Summary
The motion-picture-industry themed ocrelizumab RA program won't be taking home any awards with the FILM study on clinical hold and the SCRIPT trial halted after deaths from infection.